🔗 Share this article

As the United States proceeds with historic revisions to its vaccine schedules, one figure has surfaced in a surprising turn: Høeg, an American of Danish descent sports physician and epidemiologist who first made her name by expressing skepticism about COVID-19 vaccinations in the pandemic and has concentrated on alleged fatalities after Covid vaccination in her brief time at the FDA.

Proposed Shifts to Pediatric Vaccine Program

Public health authorities planned to reveal sweeping changes to the childhood vaccination calendar in December, bringing the US with the Danish national calendar, according to reports – a major change that would place the US out of alignment with many the global community with little proof for public health gain. This reveal has been postponed until the next year.

In place of Vinay Prasad, Dr. Høeg is listed to address the audience at the event. She was recently named temporary leader of the FDA’s CDER, the fifth person to run the office this year.

A New Direction at the FDA

The acting appointment could signify a closer partnership between the drug and biologics branches as Dr. Høeg and Dr. Prasad strengthen their influence at the FDA – and it points to a renewed priority upon dismantling long-standing immunizations at the FDA.

Dr. Høeg has repeatedly called for ending specific childhood vaccine recommendations in the US in order to be more in line with the Danish model, a society with universal health coverage and a citizenry about the size of the state of Wisconsin.

So far statements, she has kept her attention on vaccines – traditionally the domain of Dr. Prasad, head of the FDA’s CBER – instead of pharmaceutical oversight.

Questions Over Background

The appointee has no apparent background in pharmaceutical research, regulation or leadership, which has been customary for former heads of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a key advisor to the commissioner and CBER since March.

“It seems she lacks to have the necessary background” for leading the pharmaceutical oversight division, remarked Jonathan Howard. “She has not conducted a randomized controlled trial. She is not versed in leading a sizeable institution. She lacks background in industry regulation.”

Previous heads of CBER would “grasp legal statutes and the underlying principles of drug development”, said Dr. Janet Woodcock. “Frankly, she lacks the sort of resume that previous people who headed the center have had.”

This division has an immense workload at the FDA, the former commissioner pointed out.

“Many people just focuses on the novel medication approvals, but the off-patent medication office approves thousands of off-brand pharmaceuticals. There’s a biosimilars program, over-the-counter program and so forth, and every single one have to be managed,” Dr. Woodcock noted. “The area you neglect, that is the part that I always told people is going to cause problems.”

Furthermore, a significant leadership aspect to the job, which supervises in excess of 5,000 employees. “It is a enormous management job, if you perform it correctly,” the former official concluded.

Response and Controversial Programs

In response to questions about Høeg’s qualifications and whether this selection indicates greater collaboration among regulatory chiefs on vaccines, a spokesperson said that the “questions are based on incorrect assumptions”.

“Her experience aligns with the duties of her role,” the representative stated, citing the months Høeg spent guiding the agency head on “medication safety and approval science, including computational safety modeling and vaccine surveillance”.

In her interim role, Dr. Høeg takes over the commissioner’s new fast-track approval initiative, a contentious one-day drug-approval program that allegedly concerned her preceding directors. “How are these drugs being chosen for this expedited pathway? Who makes the decisions?” Howard questioned. “There is a lot of lack of transparency going on at the agency right now.”

Overall, he said, “the agency looks to be trending towards less stringent regulations of most medications, aside from shots.”

Documented Past Work on Immunizations

Concerning immunizations, Høeg has a clearer, if problematic, past, some experts said. She authored a research paper using unverified public submissions to estimate the rate of heart inflammation following COVID-19 immunization. She advised the Florida surgeon general Dr. Joseph Ladapo, who reportedly have altered data to imply COVID-19 vaccinations are more dangerous than they are.

Included in her “desired changes” for the new administration included revising regulations for new vaccines and halting “unnecessary” immunizations, she said post-election on a audio program. At the FDA, Dr. Høeg has reportedly suggested preventing adolescent males from receiving Covid vaccinations.

“She’s an all-around true believer who commences with her beliefs and works backwards to retrofit the data in a very disingenuous, untruthful manner,” Howard said.

Taking Control and a “Revenge Tour”

Dr. Høeg joined fellow dissenters, {like|